As of mid-2021 , 21 states have enacted price transparency reporting requirement laws for pharmaceutical manufacturers. With more states continuing to propose additional laws and regulations and the possibility of federal laws on the horizon, the need to analyze and understand your firm’s drug price transparency reporting obligations has never been greater. In addition, maintaining compliance and monitoring future reporting activities can be a challenge without experienced professionals and an established, structured process to follow.

To help life sciences companies understand and comply with the myriad of ever-changing state drug price transparency reporting requirements, our team of Value Architects™ has put together an informative whitepaper to help alleviate the fear, uncertainty and doubt associated with navigating these regulations. Our complimentary whitepaper discusses:

  • The current landscape of state price transparency
  • Common challenges of state price transparency reporting
  • Recommendations
  • And more

For more information about this topic, or to learn how Baker Tilly’s Value Architects™ can help, contact our team.

Mark Scallon
Principal
Interoperability for health plans and healthcare providers
Next up

Implementing a strategic approach to interoperability for health plans and healthcare providers